Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition

Miquel Granell,[1] Xavier Calvo,[2,6] Antoni Garcia-Guiñón,[3] Lourdes Escoda,[4] Eugènia Abella,[5] Clara Mª Martínez,[1] Montserrat Teixidó,[3] Mª Teresa Gimenez,[4] Alicia Senín,[5] Patricia Sanz,[1] Desirée Campoy,[3] Ana Vicent,[4] Leonor Arenillas,[6] Laura Rosiñol,[2] Jorge Sierra,[1] Joan Bladé[2] and Carlos Fernández de Larrea,[2] on behalf of GEMMAC (Grup per l'estudi del mieloma i l'amiloïdosi de Catalunya)

[1]Department of Haematology, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Josep Carreras Leukemia Research Institutes, Universitat Autònoma de Barcelona; [2]Amyloidosis and Myeloma Unit, Department of Haematology, Hospital Clínic and IDIBAPS, Universitat de Barcelona; [3]Department of Haematology, Hospital Universitari Arnau de Vilanova, Universitat de Lleida; [4]Department of Haematology, Hospital Joan XXIII, Universitat Rovira i Virgili, Tarragona; [5]Department of Haematology. Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, and [6]Laboratory of Cytology. Department of Pathology, GRETNHE, IMIM Hospital del Mar Research Institute, Barcelona, Spain

Supplementary material

Table Supplementary 1. Clinical characteristics of patients with less than 5% versus those with ≥5% circulating plasma cells in peripheral blood.

Circulating plasma cells	<5%	≥5%
N (% overall)	465 (96.5)	17 (3.5)
Male, n (%)	251 (53.9)	9 (53)
Age, y. median (range)	70 (32-92)	64 (48-85)
Heavy chain, n (%):		
- IgG	276 (59.4)	9 (53)
- IgA	110 (23.7)	2 (12)
- light chain only	75 (16.1)	6 (35)
- IgD or IgM	4 (0.8)	0
Light chain, n (%):		
- kappa	301 (64.7)	7 (41)
- lambda	164 (35.3)	10 (59)
Haemoglobin, g/L. Median (range)	103 (56–171)	95 (40-144)
WBC x10^9/L. Median (range)	6.2 (0.9–22.6)	6.9 (3.7-63)
Platelets x10^9/L. Median (range)	214 (50–558)*	91 (24-242)*
Calcium, mg/dL. Median (range)	9.4 (7.2–14.8)	9.9 (9.0-15.8)
Creatinine, mg/dL. Median (range)	1.1 (0.3–12.2)	1.4 (0.6-8.0)
Lytic lesions. n (%):		
- None	211 (45.4)	10 (59)
- One to 3	229 (49.2)	5 (29)
- More than 3	25 (5.4)	2 (12)
D-S stage. n (%):		
- I	62 (13.3)	3 (17.6)
- II	197 (42.4)	3 (17.6)
- III	206 (44.3)	11 (64.7)
- B (creat >2mg/dL)	82 (17.6)	7(41)
β2-m, mg/L. median (range)	4.7 (1.0–48.0)	5.7 (2.9-31)
Albumin, g/L. median (range)	36.2 (15.0-48.9)	32 (24-45)
ISS stage. n (%):		
- I	98 (21.1)	1 (6)
- II	160 (34.4)	5 (29)
- III	173 (37.2)	10 (59)
- NA	34 (7.3)	1 (6)
LDH UNL, n (%)	70 (15.1)*	6 (35)*
Bone marrow PC, %. median (range)	39.5 (1-100)*	51 (18-95)*
Extramedullary disease, n (%)	88 (18.9)	4 (23.5)

*p<0.001. WBC: White blood cells. D-S: Durie-Salmon. β2-m: beta-2 microglobulin. ISS: International Staging System. LDH: Lactate dehydrogenase. UNL: Upper normal limit. PC: plasma cells.